Suppr超能文献

新冠后鼻-眶-脑毛霉菌病-来自印度北部的临床-真菌学研究。

Post-COVID-19 rhino-orbito-cerebral mucormycosis-A clinico-mycological study from North India.

机构信息

Department of Microbiology, ESIC Medical College & Hospital, Faridabad, India.

Department of ENT, ESIC Medical College & Hospital, Faridabad, India.

出版信息

Med Mycol. 2023 Jul 6;61(7). doi: 10.1093/mmy/myad067.

Abstract

The second wave of coronavirus disease 2019 (COVID-19), during the early 2021, lead to a devastating outbreak of mucormycosis in India. This study aimed to determine the aetiology, clinical features, comorbidities, and risk factors of rhino-orbito-cerebral mucormycosis (ROCM) and antifungal susceptibility pattern for the isolates. The study included all suspected cases of ROCM in post-COVID-19 patients attending the hospital from May to December 2021. A total of 70 patients were diagnosed with mucormycosis during the study period. The commonest presentations were rhino-orbital and rhino-orbito-cerebral in 35.7% of cases each. Diabetes mellitus was the commonest associated risk factor in 95.7% of all patients, while 78.5% of the patients were treated with corticosteroids in the recent past, and 25.7% presented with active COVID-19 pneumonia. The commonest isolate was Rhizopus arrhizus n = 14, followed by Aspergillus flavus n = 16, A. fumigatus n = 4, A. niger n = 3, Fusarium oxysporumn = 1, and Apophysomyces variabilisn = 1. Fungal species identification was done by phenotypic methods for all the isolates and DNA sequence analysis of 18 isolates, and antifungal susceptibility testing of 30 isolates was performed by commercially prepared HiMIC plate (HiMedia, Mumbai, India) using broth microdilution for amphotericin B, isavuconazole, itraconazole, voriconazole, and posaconazole. The MIC50 and MIC90 of amphotericin B for R. arrhizus strains were 0.25 and 4 μg/ml, respectively; and the MIC50 and MIC90 results for itraconazole, posaconazole, and isavuconazole were 8 and 8, 2 and 2, and 2 and 8 μg/ml, respectively. In vitro data showed that amphotericin B was the most effective antifungal against most species. The commercially available ready-to-use minimum inhibitory concentration plates are user-friendly for performing antifungal susceptibility, which may be useful in choosing appropriate regimens and monitoring emerging resistance.

摘要

2021 年初,第二波 2019 冠状病毒病(COVID-19)导致印度发生破坏性的毛霉菌病暴发。本研究旨在确定新冠病毒感染后发生的鼻窦-眶-颅毛霉菌病(ROCM)的病因、临床特征、合并症和危险因素,以及分离株的抗真菌药敏模式。该研究纳入了 2021 年 5 月至 12 月期间在我院就诊的疑似 COVID-19 后发生 ROCM 的所有患者。研究期间共诊断出 70 例毛霉菌病患者。最常见的表现是鼻窦-眶部和鼻窦-眶-颅部各占 35.7%。95.7%的患者存在糖尿病这一共同的危险因素,而 78.5%的患者近期接受过皮质类固醇治疗,25.7%的患者表现为活动性 COVID-19 肺炎。最常见的分离株是根毛霉(Rhizopus arrhizus)n = 14,其次是黄曲霉(Aspergillus flavus)n = 16、烟曲霉(A. fumigatus)n = 4、黑曲霉(A. niger)n = 3、尖孢镰刀菌(Fusarium oxysporun)n = 1 和多变根毛霉(Apophysomyces variabilis)n = 1。所有分离株均采用表型方法进行真菌种属鉴定,对 18 株分离株进行 DNA 序列分析,并采用市售 HiMIC 板(HiMedia,印度孟买)进行 30 株分离株的抗真菌药敏试验,采用肉汤微量稀释法检测两性霉素 B、伊曲康唑、伏立康唑和泊沙康唑。根毛霉(Rhizopus arrhizus)菌株的两性霉素 B 的 MIC50 和 MIC90 分别为 0.25 和 4μg/ml;伊曲康唑、泊沙康唑和伊曲康唑的 MIC50 和 MIC90 结果分别为 8 和 8、2 和 2、2 和 8μg/ml。体外数据表明,两性霉素 B 对大多数物种最有效。市售即用型最小抑菌浓度平板易于操作,适用于抗真菌药敏试验,对抗真菌药物选择和监测耐药性的出现可能有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验